{"preliminary_commentary":{"by_channel":{"x_thread":23,"podcast":3,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04469556\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"PASS-01","nct_id":"NCT04469556","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pass-01-nct04469556. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PASS-01","arms":[{"description":"Modified FOLFIRINOX (Folinic acid/Leucovorin, 5-Fluouracil, Irinotecan, Oxaliplatin) administered intravenously.\n\nGiven that both regimens are standard of care, study treatment will be administered as per standard of care at each institution including a maintenance therapy approach which is encouraged in both arms. Dose modifications, anti-emetics, supportive medications, and use of growth factors should follow institutional guidelines.","label":"Modified Folfirinox","type":"ACTIVE_COMPARATOR"},{"description":"Gemcitabine/nab-Paclitaxel administered intravenously.\n\nGiven that both regimens are standard of care, study treatment will be administered as per standard of care at each institution including a maintenance therapy approach which is encouraged in both arms. Dose modifications, anti-emetics, supportive medications, and use of growth factors should follow institutional guidelines.","label":"Gemcitabine/nab-Paclitaxel","type":"ACTIVE_COMPARATOR"}],"collaborators":["Johns Hopkins University","Cold Spring Harbor Laboratory","Ontario Institute for Cancer Research","Dana-Farber Cancer Institute","Memorial Sloan Kettering Cancer Center","Stand Up To Cancer"],"completion_date":{"date":"2025-03-05","type":"ACTUAL"},"conditions":["Pancreatic Cancer Metastatic","Pancreatic Ductal Adenocarcinoma","Advanced Pancreatic Cancer"],"enrollment":{"count":150,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Folfirinox","otherNames":["Folinic Acid/Leucovorin, 5-Fluouracil, Irinotecan, Oxaliplatin"],"type":"DRUG"},{"name":"Gemcitabine/nab-paclitaxel","otherNames":[],"type":"DRUG"}],"last_update":"2026-02-20","lead_sponsor":"University Health Network, Toronto","official_title":"Pancreatic Adenocarcinoma Signature Stratification for Treatment","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-03-05","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression free survival(PFS) in mFFX and GA arms pancreatic ductal adenocarcinoma (PDAC) in a randomized phase II trial.","timeFrame":"2-4 years"}],"references":[],"start_date":{"date":"2020-10-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Pancreatic Adenocarcinoma Signature Stratification for Treatment","url":"https://clinicaltrials.gov/study/NCT04469556"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pass-01-nct04469556"}